What is the status of Olatec's lead compound in clinical development?

In human studies to date, Olatec's lead compound, dapansutrile, has shown clinical benefit, reduction in systemic inflammation, and a clean safety profile.

Who is part of Olatec's drug development team?

Olatec's drug development team is comprised of experienced management and international thought leaders who have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today.

Voyager DB

Search millions of small businesses and reveal verified decision-makers.

Contact Research

Hand-built prospect lists from human researchers, delivered in 24 hours.

Chrome Extension

Coldlytics in your browser - prospect any business as you browse the web.

Olatec Therapeutics

$7.2M revenue • 40 employees • United States

Last Updated May 21, 2025

Own this business? Claim & update this listing →

Company Overview

Company Name

Olatec Therapeutics

Address

United States

Website

olatec.com

Phone

(833) 652-8321

Approx. Annual Revenue

$7.2M

Employees

Established

2014

About Olatec Therapeutics

Olatec is a privately held biopharmaceutical company based in the United States. Established in 2014, the company employs approximately 2 people and is dedicated to developing and commercializing a platform of safe, oral NLRP3 antagonist therapeutics to treat a broad spectrum of inflammatory diseases.

More Companies in New York

Browse all companies in New York →

Frequently Asked Questions about Olatec Therapeutics

Technologies Used

Google Analytics

Social Profiles

Key Decision Makers

Damaris Skouras Founder & CEO

Nadia Baichoo Study Contact